



Immune Design  
Investor Relations Department  
Immune Design Corp. Attn:  
Accounts Payab  
601 Gateway Blvd. Suite 250  
South San Francisco, CA 94080  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: IMDZ

Last Trade:	8.40
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	4.50 - 13.05
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [Aug 2, 2017  
Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update](#)
- [Jul 26, 2017  
Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update](#)
- [Jun 5, 2017  
Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting](#)
- [Jun 1, 2017  
Immune Design to Present at Jefferies 2017 Global Healthcare Conference](#)
- [May 17, 2017  
New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms](#)

## Financials [\[ View all \]](#)

- [Second Quarter Financial Results](#)
- [Mar 7, 2017  
Annual Report \(10-K\)](#)
- [Apr 26, 2017  
Proxy Statement \(DEF 14A\)](#)
- [Aug 2, 2017  
Quarterly Report \(10-Q\)](#)
- [May 4, 2017  
Quarterly Report \(10-Q\)](#)
- [Nov 9, 2016  
Quarterly Report \(10-Q\)](#)